AMPs hold promise to act as lead compounds for the generation of novel therapeutic agents with fast and wide spectrum of activity, low capacity to induce resistance while displaying relevant immunomodulatory functions (e.g. LPS detoxification; wound-healing). However, a lot of AMPs loss their antimicrobial activity in biological environments and only a limited number of studies have been carried out to demonstrate the in vivo effect(s) of AMPs or derivatives in animal models of P. aeruginosa-induced lung infection.